Abstracts tagged "Deucravacitinib"

Abstract Number: 0509 • ACR Convergence 2021
Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Anjaneya Chimalakonda¹, James Burke¹, Lihong Cheng¹, Ian Catlett¹, Michael Tagen¹, Qihong Zhao¹, Aditya Patel¹, Jun Shen¹, Ihab Girgis¹, Subhashis Banerjee¹ and John Throup², ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol Myers Squibb, Princeton
Background/Purpose: Deucravacitinib is a novel, oral, allosteric agent that selectively inhibits intracellular signaling by binding to the tyrosine kinase 2 (TYK2) pseudokinase domain rather than…
Abstract Number: 1820 • ACR Convergence 2021
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Tom Lehman⁶, Lan Wei⁶, Marleen Nys⁷, Subhashis Banerjee⁶ and Miroslawa Nowak⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Braine-l'Alleud, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2…